Trial · NCT00970073
Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant
NCT00970073, Not applicable, Completed, The Cleveland Clinic; results first posted 2018-10-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant. Trials, record NCT00970073. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00970073
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant
- NCT number
- NCT00970073
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 30 participants, actual
- Lead sponsor
- The Cleveland Clinic
- Conditions
- Liver Transplantation
- Interventions
- Thymoglobulin 3mg total, Thymoglobulin 4.5mg total, Mycophenolate mofetil, tacrolimus 3-8, tacrolimus 8-12
- First posted
- 2009-09-02
- Last updated
- 2018-10-09
- Results first posted
- 2018-10-09
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Estimated Glomerular Filtration Rate (eGFR) at 12 Months Post-surgery | 12 Months | Postoperative acute kidney injury is measured as reduced (eGFR) within 12 months post-surgery. |
| Secondary | Patient Survival | 12 months post-transplant | |
| Secondary | Graft Survival | 12 months post transplant | 90% graft survival, related to the deaths of 3 patients during the study period. |
| Secondary | Allograft Rejection Rates at 30 Days | 30 days | Acute Allograft Rejection |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Estimated Glomerular Filtration Rate (eGFR) at 12 Months Post-surgery | 12 Months | mL/min | MEDIAN | |
| SECONDARY | Patient Survival | 12 months post-transplant | Kaplan- Meier | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Graft Survival | 12 months post transplant | Kaplan Meier for patient survival | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Allograft Rejection Rates at 30 Days | 30 days | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Estimated Glomerular Filtration Rate (eGFR) at 12 Months Post-surgery | Delayed CNI Group 1 | 72 | 90% Confidence Interval 57.7 to 86.3 | mL/min | |
| Estimated Glomerular Filtration Rate (eGFR) at 12 Months Post-surgery | Delayed CNI Group 2 | 87.8 | 90% Confidence Interval 67.3 to 108.3 | mL/min | |
| Estimated Glomerular Filtration Rate (eGFR) at 12 Months Post-surgery | Early CNI / Control Arm | 51.0 | 90% Confidence Interval 24.4 to 77.6 | mL/min | |
| Patient Survival | Delayed CNI Group 1 | 10 | Participants | ||
| Patient Survival | Delayed CNI Group 2 | 9 | Participants | ||
| Patient Survival | Early CNI / Control Arm | 8 | Participants | ||
| Graft Survival | Delayed CNI Group 1 | 10 | Participants | ||
| Graft Survival | Delayed CNI Group 2 | 9 | Participants | ||
| Graft Survival | Early CNI / Control Arm | 8 | Participants | ||
| Allograft Rejection Rates at 30 Days | Delayed CNI Group 1 | 3 | Participants |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Delayed CNI Group 1 | 10 | |
| Overall Study | STARTED | Delayed CNI Group 2 | 10 | |
| Overall Study | STARTED | Early CNI / Control Arm | 10 | |
| Overall Study | COMPLETED | Delayed CNI Group 1 | 10 | |
| Overall Study | COMPLETED | Delayed CNI Group 2 | 10 | |
| Overall Study | COMPLETED | Early CNI / Control Arm | 10 | |
| Overall Study | NOT COMPLETED | Delayed CNI Group 1 | 0 | |
| Overall Study | NOT COMPLETED | Delayed CNI Group 2 | 0 | |
| Overall Study | NOT COMPLETED | Early CNI / Control Arm | 0 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | HCV recurrence | Infections and infestations | Delayed CNI Group 1 | 2 | 10 | 2 |
| other | HCV recurrence | Infections and infestations | Delayed CNI Group 2 | 5 | 10 | 5 |
| other | HCV recurrence | Infections and infestations | Early CNI / Control Arm | 4 | 10 | 4 |
| serious | Metastatic Lung Cancer | Respiratory, thoracic and mediastinal disorders | Delayed CNI Group 1 | 0 | 10 | 0 |
| serious | Metastatic Lung Cancer | Respiratory, thoracic and mediastinal disorders | Delayed CNI Group 2 | 1 | 10 | 1 |
| serious | Metastatic Lung Cancer | Respiratory, thoracic and mediastinal disorders | Early CNI / Control Arm | 0 | 10 | 0 |
| serious | Graft vs Host Disease | Immune system disorders | Delayed CNI Group 1 | 0 | 10 | 0 |
| serious | Graft vs Host Disease | Immune system disorders | Delayed CNI Group 2 | 0 | 10 | 0 |
| serious | Graft vs Host Disease | Immune system disorders | Early CNI / Control Arm | 1 | 10 | 1 |
| serious | Heart Failure | Cardiac disorders | Delayed CNI Group 1 | 0 | 10 | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Delayed CNI Group 1 | 0 | 10 |
| Total, all-cause mortality | Delayed CNI Group 2 | 1 | 10 |
| Total, all-cause mortality | Early CNI / Control Arm | 2 | 10 |
| Total, other adverse events | Delayed CNI Group 1 | 2 | 10 |
| Total, other adverse events | Delayed CNI Group 2 | 5 | 10 |
| Total, other adverse events | Early CNI / Control Arm | 4 | 10 |
| Total, serious adverse events | Delayed CNI Group 1 | 0 | 10 |
| Total, serious adverse events | Delayed CNI Group 2 | 1 | 10 |
| Total, serious adverse events | Early CNI / Control Arm | 1 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00970073
GET https://conductscience.org/api/trials/v1/NCT00970073/registered